TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06330259

Intervention type: DIAGNOSTIC_TEST
Intervention: menstrual cycle monitoring
Description: frequent serum sampling and 3D ultrasound

Intervention type: DIAGNOSTIC_TEST
Intervention: menstrual cycle monitoring
Description: frequent serum sampling and 3D ultrasound
Study: NCT01772732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simotinib Hydrochloride
Study: NCT00595478

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)/CBT+CM
Description: Behavioral Treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Enhancement Therapy (MET)/CBT
Description: Behavioral Treatment
Study: NCT03401671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanadelumab
Description: SC injection of 300mg in 2mL (150 mg/mL) solution of lanadelumab will be administered as a single dose injection in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanadelumab
Description: SC injection of 300mg in 2mL (150 mg/mL) solution of lanadelumab will be administered as a single dose injection in the abdomen.
Study: NCT01635855

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belotero®
Description: Hyaluronic acid dermal filler
Study: NCT02218034

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tazarotene cream 0.1%
Description: Tazarotene cream 0.1% cream applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
Study: NCT03764241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 15mg/QD will be applied for 3 months unless severe safety outcome occurs. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.
Study: NCT00293995

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Repair of unilateral inguinal hernia

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Repair of unilateral inguinal hernia
Study: NCT02487004

Intervention type: DEVICE
Intervention: hemodialysis
Study: NCT00550693

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Chlorhexidine-impregnated foam dressing
Description: Patients during the intervention period had this foam dressing applied around their central venous catheter. This was replaced once a week as recommended by the package insert unless the dressing was soiled, bloody, or fell off.
Study: NCT04030793

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Individualized transcranial direct current stimulation
Description: Based on tDCS stimulation, individualized stimulation during 30 minutes with sitting position.
Study: NCT00159588

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betablockers or other preventive drugs based on primary headache type
Description: Several preventive drugs based on each individual regarding type of original headache type (i.e angiotensin II blockers, betablockers, valproate, tricyclic antidepressants or gabapentin)
Study: NCT02633956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid
Description: Once a day (QD) by mouth (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid
Description: Once a day (QD) by mouth (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid
Description: Once a day (QD) by mouth (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).~Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.~Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).~Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.~Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).~Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.~Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).~Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.~Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once a day (QD) by mouth (PO)
Study: NCT02567461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg
Description: Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban 30 mg
Description: Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75 mg
Description: Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg
Description: Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg
Description: Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81 mg
Description: Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
Study: NCT04030793

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional transcranial direct current stimulation
Description: Conventional tDCS stimulation during 30 minutes with sitting position.
Study: NCT03764241

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K Antagonist
Description: warfarin (INR 2.0-2.5) will be applied for 3 months unless severe safety outcome occur. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.
Study: NCT03389217

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-tDCS + rehabilitation programme
Description: tDCS stimulation will be delivered using a constant current stimulator, with rechargeable batteries. The active electrode will be placed on the left dorsolateral prefrontal cortex (DLPFC) and the reference electrode will be placed over the controlateral supraorbital region. The direct current will be delivered through a pair of sponge electrodes with a surface of 35 cm2 (7 × 5), soaked in saline solution. This continuous stimulation will last 30 minutes, with an intensity of 1 mA. Rehabilitation programme will last for 30 minutes and includes specific exercises for prevention and management of pain. All the subjects enrolled will receive treatments for 4 weeks. During the first week the experimental group underwent tDCS daily (Monday-Friday) and rehabilitation programme 3 days per week. tDCS will be delivered before rehabilitation treatment. During the second, third and fourth week subjects will receive only rehabilitation treatment, 3 days per week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham-tDCS + rehabilitation programme
Description: The control group will receive the same protocol treatment but they underwent sham-tDCS during the first week of treatment. For sham condition tDCS, current was delivered for only 30 seconds and then the current was discontinued, but the tDCS apparatus was left in place for the same time as active tDCS (30 minutes)
Study: NCT02964442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Capsinoids
Description: 12 mg of Gel capsules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Stimulus
Description: Cooling vest maintain at 14 degree Celsius
Study: NCT01795846

Intervention type: OTHER
Intervention: Allergen specific immunotherapy and placebo injections

Intervention type: OTHER
Intervention: Allergen specific immunotherapy and placebo injections
Study: NCT03853993

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine
Description: Received single dose QIV (15µg/0.5ml)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine
Description: Received single dose QIV (15µg/0.5ml)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine (contains B/Victoria strain)
Description: Received single dose TIV which contains B/Victoria strain (15µg/0.5ml)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine (contains B/Yamagata strain)
Description: Received single dose TIV which contains B/Yamagata strain (15µg/0.5ml)
Study: NCT00167414

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypofractionated Stereotactic Body Radiation Therapy
Description: Hypofractionated Stereotactic Body Radiation Therapy
Study: NCT02567461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Description: Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
Study: NCT01196832

Intervention type: PROCEDURE
Intervention: blood sample
Description: blood sample for fibrocytes analysis

Intervention type: PROCEDURE
Intervention: blood sample
Description: blood sample for fibrocytes analysis

Intervention type: PROCEDURE
Intervention: Clinical and functional evaluation
Description: Plethysmography, Carbon monoxide capacity of transfer , arterial gaz
Study: NCT00848783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Study: NCT00167414

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Stereotactic Body Radiation Therapy
Description: Hypofractionated Stereotactic Body Radiation Therapy for treatment of limited metastases from breast cancer primary.
Study: NCT05058599

Intervention type: DIAGNOSTIC_TEST
Intervention: DM
Description: A new technology based on 3D reconstruction and deep learning algorithm to irreversibly erase the biometric attributes whilst retaining the clinical attributes needed for diagnosis and management
Study: NCT03256591

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HBB facilitators with simulation training
Description: HBB training from facilitators with simulation skills. Standard HBB facilitators do not have simulation skills
Study: NCT00848783

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study: NCT03878784

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imigran
Description: All patients will undergo this intervention on one of two study days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Saline
Description: All patients will undergo this intervention on one of two study days
Study: NCT00825812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium intravenous (IV) could be administered if necessary. At reappearance of T2 after the last administration of rocuronium, an IV single bolus dose of 2.0 mg/kg sugammadex was administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium intravenous (IV) could be administered if necessary. At reappearance of T2 after the last administration of rocuronium, an IV single bolus dose of 2.0 mg/kg sugammadex was administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine
Description: After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary. At reappearance of T2 after the last administration of rocuronium, an IV single bolus dose of 50 µg/kg neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine
Description: After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary. At reappearance of T2 after the last administration of rocuronium, an IV single bolus dose of 50 µg/kg neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.
Study: NCT03360474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delirium Screen
Description: Patients who screen positive for delirium will be assessed for pain, electrolyte imbalances,infection, the use of deliriogenic medications and any issues will be resolved. Those with persistent delirium following all other intervention will be treated with antipsychotic medication.
Study: NCT03075358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine spray
Description: Patients are locally anesthetized with 8 puffs (80 mg, 10mg/puff, 0.8 ml) of 10% lidocaine spray applied thoroughly to the cervix, 3 minutes before starting the procedure.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normal saline spray
Description: 0.8 ml of normal saline spray is applied to the cervix, 3 minutes before starting the procedure
Study: NCT02956798

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiation (SABR)
Description: SAbR treatment regimens including ≥25Gy x1 fraction, ≥12Gy x 3 fractions, or ≥8Gy x 5 fractions.
Study: NCT05002491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High protein diet
Description: Normal vs high protein dietary feeding
Study: NCT02360228

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tACS (alpha)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS (alpha)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Study: NCT02095080

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine intake
Description: Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
Study: NCT01680744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypothermia
Description: The intervention will take place after consent for donation and research has been obtained and hemodynamic stability has been achieved (mean arterial blood pressure \> 60 mmHg for more than one hour without an increase in vasopressors). Organ donors in the experimental group will either be actively warmed or allowed to spontaneously reach a body temperature of 34 °C.
Study: NCT00307203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion SR
Description: Participants were randomly assigned to receive bupropion SR 150 mg or placebo, once daily for 7 days, then twice daily for 11 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Group Therapy
Description: Participants attended a 12-session, 1-hour, weekly smoking cessation group program with 3 to 7 participants led by a psychologist with tobacco treatment specialist training. Subjects set a quit date, and nicotine patches (Habitrol) and nicotine polacrilex gum (Nicorette) were initiated in the fourth week.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Group Therapy
Description: Participants attended a 12-session, 1-hour, weekly smoking cessation group program with 3 to 7 participants led by a psychologist with tobacco treatment specialist training. Subjects set a quit date, and nicotine patches (Habitrol) and nicotine polacrilex gum (Nicorette) were initiated in the fourth week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine replacement therapy
Description: Nicotine patch was dosed at 21 mg/d for 4 weeks, 14 mg/d for 2 weeks, and 7 mg/d for 2 weeks, then discontinued. Nicotine gum (2 mg) was distributed for use as needed for craving up to 18 mg/d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nicotine replacement therapy
Description: Nicotine patch was dosed at 21 mg/d for 4 weeks, 14 mg/d for 2 weeks, and 7 mg/d for 2 weeks, then discontinued. Nicotine gum (2 mg) was distributed for use as needed for craving up to 18 mg/d.
Study: NCT02059603

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fast-track program
Study: NCT01429181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-racemic mixture of methadone HCl
Description: Non-racemic mixture of methadone HCl capsules, 5 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non-racemic mixture of methadone HCl
Description: Non-racemic mixture of methadone HCl capsules, 5 mg
Study: NCT03528265

Intervention type: DEVICE
Intervention: Lateral flow immunoassay
Description: Biospecimens of patients with melioidosis-like symptoms will be tested with lateral flow immunoassay to detect Burkholderia pseudomallei, bacterium causing melioidosis
Study: NCT01652040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resistance Training and Testosterone Patches
Description: We are going to activate the knee extensor muscle group to lift ankle weights over 16 weeks and we are going to provide Tp to improve anabolic profile.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Patches
Description: The investigators will provide Tp patches for 16 weeks for patients with Spinal Cord Injury.
Study: NCT01593761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG400549
Description: 960mg QD at fed state approx 1 hour after meal
Study: NCT05765994

Intervention type: DIAGNOSTIC_TEST
Intervention: Modified hydrogen breath test
Description: A modified technique to obtain expired hydrogen from the ventilator tubes is performed. A connection with a valve attached to a collecting bag is inserted at the end of the expiratory limb of the breathing circuit for exhaled air collection.
Study: NCT05361005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDB-001 injection
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDB-001 injection
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDB-001 injection
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDB-001 injection
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous injection
Study: NCT01090648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etravirine
Description: One etravirine (ETR) 200 mg uncoated oral tablet and one etravirine (ETR) 200 mg film-coated tablet
Study: NCT02059473

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rotator cuff repair
Description: Physiotherapy \& Surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Study: NCT01188304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: repeated daily doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Description: repeated daily doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: aspirin
Description: repeated daily doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: repeated daily doses
Study: NCT01667653

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotic capsule once daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule once daily
Study: NCT03662516

Intervention type: DRUG
Group type: OTHER
Intervention: PF-04965842
Description: Orally bioavailable small molecule that selectively inhibits JAK 1 by blocking the adenosine triphosphate (ATP) binding site.

Intervention type: DRUG
Group type: OTHER
Intervention: PF-04965842
Description: Orally bioavailable small molecule that selectively inhibits JAK 1 by blocking the adenosine triphosphate (ATP) binding site.

Intervention type: DRUG
Group type: OTHER
Intervention: Ethinyl estradiol (EE) and levonorgestrel (LN)
Description: Single dose of Oral tablet containing 30 ug EE and 150 ug of LN

Intervention type: DRUG
Group type: OTHER
Intervention: Ethinyl estradiol (EE) and levonorgestrel (LN)
Description: Single dose of Oral tablet containing 30 ug EE and 150 ug of LN